Nicholson Wealth Management Group LLC acquired a new position in Medtronic plc (NYSE:MDT – Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 6,472 shares of the medical technology company’s stock, valued at approximately $583,000.
Other large investors also recently added to or reduced their stakes in the company. Lynx Investment Advisory bought a new stake in shares of Medtronic during the 2nd quarter valued at about $28,000. Tributary Capital Management LLC bought a new stake in Medtronic during the first quarter valued at approximately $33,000. Gleason Group Inc. bought a new stake in Medtronic during the second quarter valued at approximately $42,000. Opal Wealth Advisors LLC purchased a new position in Medtronic in the 2nd quarter worth approximately $43,000. Finally, Olistico Wealth LLC bought a new position in shares of Medtronic in the 2nd quarter worth $45,000. Institutional investors own 82.06% of the company’s stock.
Medtronic Stock Down 1.4 %
Shares of NYSE MDT opened at $90.99 on Friday. The firm’s fifty day moving average is $89.04 and its 200 day moving average is $83.74. Medtronic plc has a 52 week low of $68.84 and a 52 week high of $92.68. The company has a quick ratio of 1.61, a current ratio of 2.13 and a debt-to-equity ratio of 0.55. The company has a market cap of $116.67 billion, a price-to-earnings ratio of 33.09, a PEG ratio of 2.53 and a beta of 0.84.
Medtronic Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 11th. Shareholders of record on Friday, September 27th were issued a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 3.08%. The ex-dividend date of this dividend was Friday, September 27th. Medtronic’s dividend payout ratio (DPR) is currently 101.82%.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the stock. Truist Financial lifted their price objective on shares of Medtronic from $90.00 to $93.00 and gave the stock a “hold” rating in a report on Monday, October 14th. Daiwa America raised Medtronic to a “strong-buy” rating in a research note on Friday, August 23rd. Oppenheimer increased their price objective on Medtronic from $92.00 to $94.00 and gave the company a “market perform” rating in a research report on Wednesday, August 21st. Wells Fargo & Company boosted their target price on Medtronic from $105.00 to $106.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Finally, Royal Bank of Canada raised Medtronic from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $98.00 to $105.00 in a research note on Thursday, October 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Medtronic currently has a consensus rating of “Hold” and a consensus target price of $95.36.
Get Our Latest Stock Analysis on MDT
Medtronic Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Featured Stories
- Five stocks we like better than Medtronic
- The How And Why of Investing in Oil Stocks
- Maximize Portfolio Income with These 3 Dividend ETFs
- 3 Warren Buffett Stocks to Buy Now
- Talen Energy: A Nuclear Power Stock That Can Keep Winning
- Investing in Commodities: What Are They? How to Invest in Them
- Rocket Lab Stock Soars Higher: Can It Keep Climbing?
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.